Loss of heterozygosity (LOH) on chromosome 10 has been observed in several human cancers including glioblastomas, meningiomas, melanomas and endometrial and prostate carcinomas. We have investigated the incidence of LOH on chromosome 10 in 36 human transitional cell carcinomas (TCCs) of the bladder, three upper urinary tract TCCs and one lymph node metastasis, using a panel of 27 highly polymorphic markers spanning 10p (short arm) and 10q (long arm). Fourteen bladder tumours (39%), the three upper urinary tract tumours and the lymph node metastasis showed LOH for at least one locus on chromosome 10. Remarkably, LOH on chromosome 10 was observed mainly in muscle-invasive (P=0.01) and high grade tumours (P=0.03). For ®ve tumours and the lymph node metastasis, LOH was found at all informative loci, indicating monosomy or isodisomy of chromosome 10. The deletion mapping of the tumours with partial loss delineated two minimal regions of loss on chromosome 10q. One region, the most telomeric, was bounded by markers D10S214 and D10S169 and the other, the most proximal, was bounded by markers D10S222 and D10S531. Our results demonstrate that chromosome 10q LOH is common in muscle-invasive bladder cancers and that two potential tumour suppressor loci, at 10q24.1-q24.3 and 10q26.1-q26.2, may contribute to the malignant progression of these tumours. Localization of the smallest common regions of loss in bladder tumours provides a starting point for the identi®cation of the genes involved.
Introduction
The genetic analysis of tumour development has now widely demonstrated that oncogenesis involves both activation of protooncogenes and inactivation of tumour suppressor genes (Knudson, 1993) . Nonrandom loss of heterozygosity (LOH) of chromosomal regions has often been observed in epithelial malignancies (Rodriguez et al., 1994) and, on the basis of Knudson's two hits model, these areas are likely to harbour critical tumour suppressor genes. Moreover, LOH analysis has underlined the importance of loci unlinked to cancer predisposing syndromes. Fine analysis of these somatic genetic alterations thus represents a useful tool for the understanding of the molecular mechanisms of carcinogenesis.
Transitional cell carcinomas (TCCs) of the urinary bladder are common in the Western World and aect both men and women (Wingo et al., 1995) . Most of the bladder tumours do not invade the muscular layer at the time of diagnosis but often recur and sometimes progress to muscle-invasive disease. Another subgroup of patients present with invasive disease (Kaye and Lange, 1982) . Patients with muscle-invasive tumours have a de®nitive risk of distant metastasis warranting radical therapy. Therefore bladder cancers provide an important model to study the genetics of tumour progression and metastasis (Spruck et al., 1994) .
Molecular analyses of bladder tumours have demonstrated that the most common genetic event is allelic loss on chromosome 9 (Knowles et al., 1994) , and that both 9p and 9q may harbour tumour suppressor genes involved in the initiation of bladder tumorigenesis Cairns et al., 1993; Ruppert et al., 1993; Habuchi et al., 1995) . LOH has also been observed at 13q14 and 17p13 (the RB and p53 loci, respectively) as well as at other loci on chromosome 3p, 4p and 4q, 5q, 8p, 11p, 14q and 18q, and was associated with TCC progression (Fearon et al., 1985; Olumi et al., 1990; Cairns et al., 1991; Sidransky et al., 1991; Dalbagni et al., 1993; Knowles et al., 1993; Brewster et al., 1994; Chang et al., 1995; Polascik et al., 1995) .
LOH on chromosome 10 has been described in several tumour types including glioblastomas, meningiomas, melanomas and uterine and prostate carcinomas (Fults and Peldone, 1993; Herbst et al., 1994; Gray et al., 1995; Peier et al., 1995; Rasheed et al., 1995; Simon et al., 1995; Trybus, et al., 1996; Ittman, 1996) . In spite of cytogenetic reports (Gibas et al., 1984; Atkin and Baker 1985; Berger et al., 1986; Babu et al., 1987; Smeets et al., 1987) and comparative genomic hybridization or¯uorescent in situ hybridization studies (Wang et al., 1994; Kallioniemi et al., 1995) describing frequent monosomies of chromosome 10 and 10q deletions in bladder tumours, the incidence of chromosome 10 loss in bladder TCCs has not been investigated in detail.
In the present report, we describe the analysis of a representative panel of 36 bladder tumours of various stages and grades, as well as three upper urinary tract TCCs and one lymph node metastasis, for LOH on chromosome 10, and the identi®cation of the putative suppressor loci. Our results indicate that LOH on chromosome 10 is associated with malignant progression of bladder tumours and de®ne 10q24.1-q24.3 and 10q26.1-q26.2 as the smallest regions of overlap.
Results
Chromosome 10 loss of heterozygosity analysis of transitional cell carcinomas
We have examined 36 bladder TCCs, three upper urinary tract TCCs and one lymph node metastasis from 33 patients (see Table 1 ) for chromosome 10 LOH with a panel of 27 highly informative polymorphic markers (six on 10p and 21 on 10q) listed in Table 2 . Paired constitutional and tumour DNAs were analysed for each marker by semi-quantitative polymerase chain reaction (see Materials and methods). All patients were informative for several markers on the p and q arms. LOH was observed in 14 bladder tumours (39%), as well as in the three upper urinary tract tumours and the lymph node metastasis. Six of the 36 bladder tumours (17%) and the lymph node metastasis had LOH on both 10p and 10q. The remaining eight bladder tumours (22%) and the three upper urinary tract tumours had LOH on 10q alone. None of the 40 tumour samples analysed had LOH on 10p alone (Table 2 and data not shown).
Correlation between chromosome 10 LOH and tumour stage and grade
The distribution of chromosome 10 LOH in tumours of dierent stages and grades (see Table 1 ) is shown in Tables 3 and 4 . The determination of allelic loss was carried out without prior knowledge of the clinical histopathological features. For these correlation studies, the lymph node metastasis (342.2b, see Table  1 ) was not taken into account. Patient 1533 presented with two physically independent bladder lesions (1533.a,b) and three upper urinary tract TCCs (1533 c, d and e) (see Table 1 ). Since every tumour sample obtained from this patient displayed chromosome 10 LOH and may be related, we considered only one sample from this patient for the statistical analysis. A signi®cant correlation was found between LOH and high tumour stage, since we observed LOH mainly in 5T2 lesions and in only two T1 lesions, one of which presented with associated carcinoma in situ and rapidly progressed to lethal metastatic disease (two-sided P=0.01, Fisher's exact test) (Table 3 ). There was also an association between LOH and high tumour grade (G1 and G2 versus G3, two-sided P=0.03, Fisher's exact test) ( Table 4) .
Deletion map of chromosome 10 in transitional cell tumours
The deletion map of the dierent TCCs, including the critical tumours with partial loss, is presented in Table  2 and points out the presence of two minimal regions of LOH on chromosome 10q. Markers have been placed on the chromosome 10 ideogram (Figure 1 ) according to Bray-Ward and colleagues and the CEPH-Genethon, Genome Database and Whitehead Institute/MIT Center for Genome Research databases (Bray-Ward et al., 1996 ; see Material and methods for the Internet databases URLs). When a marker was not informative and located at the border or within a deleted region, we decided to include it in the deleted region, to prevent any bias that could minimize the common region of deletion.
The most proximal area is con®ned to a region bordered by markers D10S222 and D10S531, between cytogenetic bands 10q24.1 and 10q24.3, and spans approximately 10 cM. Tumour 505.1 de®nes the centromeric breakpoint and tumour 1398 de®nes the telomeric breakpoint. The most distal area is bordered by markers D10S214 and D10S169, between cytogenetic bands 10q26.1 and 10q26.2, and spans approximately 10 cM. Tumour 505.1 de®nes the centromeric breakpoint and tumour 1077 de®nes the telomeric breakpoint. Tumours 505.1 and 1533.b lost both loci with a region of retention in between (Table 2 and Figures 2 and 3) .
The autoradiograms of the three tumours de®ning the breakpoints are shown in Figure 2 . An additional ®ve tumours (1033, 1393, 1472, 1512 and 1533.a) Ta  Ta  Ta  Ta  Ta  Ta  T1a  T1a  T1a  T1a  T1a  T1a  T1a+cis  T1b  T1b  T2  T3  T2  T2  T2  T3  T3  T3  T3  T3  T3  T3  T3  T4  T4  T4  T4  T1a  T4  N+  T4  T4  ±  ±  ±   G2  G1  G1  G2  G2  G2  G1  G2  G2  G2  G2  G3  G3  G2  G2  G2  G2  G2  G2  G3  G2  G2  G2  G2  G3  G3  G3  G3  G3  G3  G3  G3  G1  G3  ±  G3  G3  ± Table 2 . The ®ve remaining tumours (877, 910, 943, 1211 and 342.2a ) and the lymph node metastasis (342.2b) displayed LOH at all informative loci on chromosome 10 (Table 2 and data not shown).
Tumour heterogeneity and time course of chromosome 10 LOH during progression of transitional cell carcinomas
In most of the tumours with allelic losses, involving either the whole of chromosome 10 or a single region on this chromosome, the degree of signal reduction of the lost allele was almost the same for the dierent markers studied, suggesting that a single event was responsible for this genetic defect. For patients 505 and 1533, however, the pattern of LOH observed suggested the occurrence of two events involving dierent chromosome 10 loci and the presence of dierent clones of cancer cells. The genetic analysis of several tumour samples from patient 342 was also instrumental in the elucidation of the chronology of those events during progression of transitional cell carcinomas. Tumour 505.1 had a 60 ± 70% signal reduction at loci D10S575, D10S169 and D10S212 and, on the other hand, the same DNA showed only a 40% signal reduction at loci D10S168 and D10S221 (Figure 2 ). These observations indicate that this tumour may be composed of an heterogeneous population of cancer cells, 60 ± 70% of which lost 10q26-qter and 40% of which lost the 10q24.1-q24.3 region, with a region of retention in between.
Two tumour samples simultaneously resected from distinct foci of the bladder of patient 1533 (1533.a and 1533.b, see Table 1 ) were analysed for chromosome 10 LOH. Tumour 1533.a displayed LOH for the distal region only, whereas tumour 1533.b displayed LOH for both the distal and proximal loci (Table 2 and Figure  3) . In tumour 1533.a, the degree of signal reduction observed for the lost allele at locus D10S190 was about 45%. In tumour 1533.b, loci D10S185, Mxi1, D10S168 (proximal region of loss) and D10S190 (distal region of loss) displayed a 90% signal reduction (Figure 3 and data not shown). When we analysed three dierent samples obtained from bilateral surgery of the upper urinary tract (renal pelvis, calyces) of patient 1533 
The numerator is the number of tumours of the speci®ed grade with LOH at any locus on chromosome 10. The denominator is the number of informative tumours of that grade. Numbers in parentheses, percentages (two-sided P=0.03, Fisher's exact test) Figure 3 and data not shown). For patient 342, LOH was found at every informative marker on chromosome 10 in two dierent samples obtained from the same recurrent bladder lesion (342.2a) (Table 2 and data not shown), as well as in a lymph node metastasis (342.2b) (data not shown). A previous tumour obtained several years before from the same patient (342.1, see Table 1 ), although displaying a faint (20%) but reproducible signal reduction for every informative marker (data not shown), was not scored as LOH positive because this imbalance was below the ®xed limit (40%). When considering the data obtained from this patient, after recurrence and progression of the tumour, it is likely that the ®rst tumour diagnosed already contained some cells displaying chromosome 10 LOH, and that these cells, through increased growth or invasive properties, have been selected during progression of the disease.
Discussion
Until now, in spite of cytogenetic reports (Gibas et al., 1984; Atkin and Baker, 1985; Berger et al., 1986; Babu et al., 1987; Smeets et al., 1987) and comparative genomic hybridization or¯uorescent in situ hybridization studies (Wang et al., 1994; Kallioniemi et al., 1995) describing frequent chromosome 10 monosomies and deletions in bladder tumours, the role of chromosome 10 loss in bladder cancer has not been investigated in detail.
In a recent report of human bladder TCC allelotype (Knowles et al., 1994) , LOH on 10p was observed in three of 60 (5%) and LOH on 10q in ®ve of 59 (8.5%) informative cases, by examining ®ve restriction fragment length polymorphisms (RFLPs) at three loci. Considering the incidence of chromosome 10 LOH in other malignancies such as glioblastomas, meningiomas, melanomas, and endometrial and prostate carcinomas, and its association with tumour progression (Fults and Peldone 1993; Herbst et al., 1994; Gray et al., 1995; Peier et al., 1995; Rasheed et al., 1995; Simon et al., 1995; Trybus et al., 1996; Ittmann, 1996) , we decided to undertake a ®ne analysis of a representative panel of 36 bladder TCCs of dierent stages and grades, as well as three upper urinary tract TCCs and a lymph node metastasis, with 27 highly polymorphic markers spanning chromosome 10.
Our results demonstrate that the incidence of LOH on chromosome 10 in bladder TCCs has been underestimated in previous studies, and begin to clarify the role of chromosome 10 loss in the pathogenesis of bladder cancer. Indeed, in the present report, we describe a relatively high incidence of chromosome 10 LOH in transitional cell carcinomas of the bladder. Remarkably, LOH on chromosome 10 has been found only in high grade muscle-invasive tumours, except two T1G3 tumours, one of which presented with associated carcinoma in situ and progressed within 4 months to lethal metastatic disease. As described previously, carcinoma in situ is a highly aggressive lesion displaying the same genetic alterations as high stage and high grade TCCs (Spruck et al., 1994; Rosin et al., 1995) .
The deletion map of the tumours displaying partial chromosome 10 LOH delineated two smallest regions of overlap on chromosome 10q. The most telomeric region, at 10q26.1-q26.2, was bounded by markers D10S214 and D10S169 and the most proximal, at 10q24.1-q24.3, was bounded by markers D10S222 and D10S531.
We have also noticed that cancer cell populations within bladder tumours were heterogeneous for the loss of dierent chromosome 10 loci. For example, in tumour 505.1, about 60 ± 70% of the tumour cells lost 10q26-qter and about 40% of these cells lost the 10q24.1-q24.3 region, thus suggesting that either 10q26-qter LOH occurred ®rst and a subset of tumour cells acquired additional genetic alterations (i.e. 10q24.1-q24.3 LOH), or that two dierent clones coexist within the tumour, one displaying 10q26-qter LOH (representing 60% of the cells) and the other displaying 10q24.1-q24.3 LOH (representing 40% of the cells). For patient 1533, tumour 1533.a displayed LOH at 10q26, tumour 1533.b displayed LOH at both 10q26 and 10q24, and three dierent samples (1533 c, d (Table 2 and Figure 3 ). The simplest explanation of two dierent cancer cell populations, one displaying 10q24 LOH and the other displaying 10q26 LOH, could be excluded as the signal reduction observed for the lost alleles at both 10q24 and 10q26 in tumour 1533.b was around 90%. One possibility would be that independent tumour cell clones lost the same allele at the same loci and display exactly the same boundaries for the deleted region. Another possibility would be the occurrence of a complex mitotic event (recombination or deletion accompanied by chromosome non-disjunction) aecting 10q24 and 10q26 simultaneously at the S/G2 phase of the cell cycle. In this latter situation, in agreement with the report of Sidransky and colleagues (Sidransky et al., 1992) , we could hypothesize a common precursor for the dierent tumour samples from this patient, with post-mitotic segregation of the cell clones having inherited dierent rearranged chromosome 10 combinations. When analysing the results reported by Rasheed and colleagues in glioblastoma (Table 1 in Rasheed et al., 1995) , and according to new physical mapping data (Bray-Ward et al., 1996) , it appeared that, in addition to the smallest common region of deletion that they mapped between markers D10S587 and D10S216, which correspond to the 10q26.1 region and is overlapping with the distal locus that we have identi®ed in TCCs, an additional minimal region of loss could be identi®ed between markers D10S468 and D10S221, at 10q24.1-q25.2, which is overlapping with the proximal region that we have identi®ed in TCCs.
Recent reports of deletion mapping of the 10q23-q25 region (Gray et al., 1995) and of the whole of chromosome 10 (Trybus et al., 1996; Ittmann, 1996) in prostate carcinomas showed that the most frequent region of LOH mapped around markers D10S541 and D10S215, corresponding to cytogenetic bands 10q22.3-q23.1 (Bray-Ward et al., 1996) . Several other loci are also probably involved, including one on chromosome 10p11.2 (Trybus et al., 1996; Ittmann, 1996) and one on chromosome 10q26-qter (Ittmann, 1996) , which is overlapping with the distal locus identi®ed in glioblastomas (Rasheed et al., 1995) and in TCCs of the bladder (present report).
Two distinct regions of LOH could also be delineated in malignant melanoma and endometrial carcinomas that may be overlapping with the two loci that we have identi®ed in bladder TCCs, although a precise comparison could not be performed because of the use of markers from dierent sources (Herbst et al., 1994; Peier et al., 1995) . Taken together, these results suggest that several 10q loci might be the target of LOH in tumours of dierent origins. The data reported herein and elsewhere also suggest that the inactivation of the genes of interest are associated with tumour progression rather than initiation. Identi®cation of those genes could thus be useful for the understanding of the molecular basis of tumour progression. It could also provide a rationale to design new therapeutic approaches.
The Mxi1 gene, which encodes a negative regulator of the Myc oncoprotein (Zervos et al., 1993) and has been proposed as a prostate tumour suppressor gene (Eagle et al., 1995) , is a potential candidate at 10q24, although mutations are rarely found in prostate carcinomas with LOH at this locus (Eagle et al., 1995; Gray et al., 1995) . However, it seems that the most frequently deleted region in prostate carcinomas maps centromeric to the Mxi1 gene (Gray et al., 1995) , whereas it always includes this gene in TCCs of the bladder (present study).
The FGFR2 gene, which encodes Fibroblast Growth Factor receptors, maps at 10q26 (Mattei et al., 1991) , between markers D10S209 and D10S587 (Ehrlich et al. and Call et al., unpublished results; International Workshop on Human Chromosome 10 Mapping, 1995). FGFR2 is a potential tumour suppressor gene since decreased expression of its two isoforms, FGFR2b (KGF-R) and FGFR2c (BEK) (Miki et al., 1992) , were shown to be associated with tumour progression in TCCs of the bladder (Gil Diez de Medina et al., 1997) and glioblastomas (Yamaguchi et al., 1994) , respectively, both of which display 10q26 LOH (present study and Rasheed et al., 1995) . Although the minimal region of loss mapping at 10q26 in TCCs is telomeric to the FGFR2 gene, 11 of the 12 tumour samples displaying 10q26 LOH included this gene in the deleted region.
We are currently searching for somatic alterations of Mxi1 and FGFR2 genes in TCCs of the bladder.
Materials and methods

Tissue specimens
Thirty-six bladder tumours, three upper urinary tract TCCs and one lymph node metastasis were obtained from 33 patients (Table 1) . Tumours were graded according to criteria recommended by the World Health Organization and staged according to the TNM classi®cation (Spiessl et al., 1992; Mosto® et al., 1973) . All the bladder tumours were transitional cell carcinomas. They consisted of six stage Ta, 10 T1 (one of which with associated carcinoma in situ), four T2, nine T3, seven T4; four were grade G1, 18 grade G2, and 14 grade G3. Of the 36 bladder tumours, 16 were super®cial and 20 were muscle-invasive. Super®cial tumours and tumour 505.1 were transurethrally resected and muscle-invasive cases, except tumour 505.1, were subjected to radical cystectomy. A representative sample was taken from each tumour for histopathological assessment, and an adjacent piece was placed in liquid nitrogen and stored at 7808C for subsequent DNA and RNA extraction. Each sample retained for the present analysis contained more than 80% tumour cells, as assessed by histopathological examination. We also veri®ed the absence of smooth muscle contamination by means of semi-quantitative RT ± PCR analysis of epithelial and muscle dierentiation markers (Gil Diez de Medina et al., 1997). Ten to twenty ml of venous blood were collected as a source of leukocytes and stored at 7208C in EDTA tubes for subsequent DNA extraction.
DNA extraction
DNA was obtained from frozen tumour samples as previously described (Coombs et al., 1990) except that, after dialysis, the samples were incubated with 100 mg/ml Proteinase K for 24 h at 378C and extracted by phenol, phenol-chloroform-isoamylic alcohol (25 : 24 : 1) and chloroform-isoamylic alcohol (24 : 1) before ethanol precipitation. Constitutional DNA was obtained from peripheral-blood leukocytes. Ten ml of venous blood was mixed with 40 ml of a solution containing 7 mM NH 4 Cl, 0.5 mM KHCO 3 , 1 mM EDTA (pH 7.4), and incubated 1 h on ice. The mononuclear cells were recovered by centrifugation, washed in the same solution and incubated overnight at 378C with 3 ml of a solution containing 1 mM EDTA (pH 7.4), 0.2 M NaCl, 5 mM Tris (pH 7.5), 1% SDS and 60 mg/ ml of Proteinase K. Two ml of 3 M NaCl were then added and the mixture was mixed vigorously. DNA was then processed as described for the tumour samples. When leukocytes were not available (one case) or when the tumour sample was contaminated by nonneoplastic tissue (two cases), DNA was extracted from paran embedded tissue sections. Normal and tumour tissues were separated by microdissection and placed in 1.5 ml vials, dewaxed in toluene, washed twice with absolute ethanol and incubated for 3 h at 558C in 50 ml of a solution containing 50 mM Tris (pH 8), 1 mM EDTA, 0.5% Tween 20 and 200 mg/ml of Proteinase K. Proteinase K was then heat inactivated and the supernatant subsequently used for polymerase chain reaction.
Loss of heterozygosity analysis
The polymorphic markers used for the analysis were dinucleotide repeats, except Mxi1 whose polymorphism consists of an AAAAC repeat in the 3' untranslated region of the gene (Albarosa et al., 1995) . The primer sequences for the microsatellites were obtained from the CEPH-Genethon, the Genome Database and Whitehead Institute/MIT Center for Genome Research Internet servers (http://www. genethon.fr/genethon_en.html; http://gdbwww.gdb.org/;http:// www-genome.wi.mit.edu/cgi-bin/contig/phys_map).
The allelic losses for each polymorphic marker studied were investigated by semi-quantitative polymerase chain reaction. The number of cycles was chosen to be in the exponential part of the PCR reaction. Indeed, we noticed that, in heterozygous samples, the ratio of the signals of the longer to the shorter allele started to decrease when the ampli®cation reaction reached the plateau, i.e. when more than 27 cycles of PCR were performed. Fifty ng of genomic DNA were subjected to PCR, performed in a ®nal volume of 25 ml containing 100 mM of each dNTP, 1 mM of each primer, 1 mCi of [a- P]ATP were added in the PCR reaction. This procedure was used for these two markers because, in informative cases, the antisense strand of an allele often had the same mobility as the sense strand of the other allele. The buer and the annealing temperature were determined empirically and optimized for each primer pair. Hi-Taq polymerase buer was used with dierent concentrations of MgCl 2 and glycerol. A hot-start protocol was performed: after an initial cycle of 958C for 5 min, 0.5 unit of Hi-Taq DNA polymerase was added to each tube, maintained at 948C, and 25 cycles, followed by a ®nal incubation step at 728C for 15 min, were performed in a PTC ± 200 Thermal Cycler (MJ Research). Each cycle consisted of denaturation at 948C for 1 min, annealing at 48 ± 648C (depending on the primer pair) for 1 min, and extension at 728C for 2 min. The PCR products were electrophoretically separated in 6% polyacrylamide-7 M urea sequencing gels after heat denaturation in a solution containing 90% formamide, 4% glycerol, 10 mM EDTA, 0.01% SDS, 0.02% xylene cyanol and bromophenol blue. Gels were dried and then exposed to storage phosphor screens. The signals were quanti®ed with a Storm 840 PhosphorImager, using the ImageQuant 4.2 software (Molecular Dynamics, Sunnyvale, CA). Loss of heterozygosity in informative cases was scored when at least a 40% change was observed in allelic ratios between the tumour and normal DNAs from the same patient. The sensitivity of our LOH analysis was determined in reconstitution experiments in which two DNA samples homozygous for dierent alleles of a particular marker were mixed in dierent ratios. In these experiments, we were reproducibly able to identify an imbalance of 20% (data not shown). A negative control of ampli®cation was included in each independent experiment by omitting the template DNA in the PCR reaction.
Abbreviations TCCs, transitional cell carcinomas; PCR, polymerase chain reaction; LOH, loss of heterozygosity.
